- Home
- ASRT vs SKYE Comparison
ASRT vs SKYE Comparison
Compare ASRT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- SKYE
- Stock Information
- Founded
- ASRT 1995
- SKYE 2012
- Country
- ASRT United States
- SKYE United States
- Employees
- ASRT N/A
- SKYE N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- SKYE Health Care
- Exchange
- ASRT Nasdaq
- SKYE Nasdaq
- Market Cap
- ASRT 85.1M
- SKYE 108.3M
- IPO Year
- ASRT 1997
- SKYE N/A
- Fundamental
- Price
- ASRT $0.87
- SKYE $2.46
- Analyst Decision
- ASRT Strong Buy
- SKYE Buy
- Analyst Count
- ASRT 4
- SKYE 6
- Target Price
- ASRT $3.19
- SKYE $18.67
- AVG Volume (30 Days)
- ASRT 917.9K
- SKYE 215.1K
- Earning Date
- ASRT 11-11-2024
- SKYE 02-09-2025
- Dividend Yield
- ASRT N/A
- SKYE N/A
- EPS Growth
- ASRT N/A
- SKYE N/A
- EPS
- ASRT N/A
- SKYE N/A
- Revenue
- ASRT $125,763,000.00
- SKYE N/A
- Revenue This Year
- ASRT N/A
- SKYE N/A
- Revenue Next Year
- ASRT $1.84
- SKYE N/A
- P/E Ratio
- ASRT N/A
- SKYE N/A
- Revenue Growth
- ASRT N/A
- SKYE N/A
- 52 Week Low
- ASRT $0.73
- SKYE $2.25
- 52 Week High
- ASRT $1.80
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- ASRT 44.85
- SKYE 25.13
- Support Level
- ASRT $0.84
- SKYE $2.39
- Resistance Level
- ASRT $0.92
- SKYE $3.55
- Average True Range (ATR)
- ASRT 0.06
- SKYE 0.33
- MACD
- ASRT -0.00
- SKYE -0.06
- Stochastic Oscillator
- ASRT 35.35
- SKYE 4.59
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.